查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年的電腦模擬臨床試驗市場預測：按治療領域、階段、應用、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383360

到 2030 年的電腦模擬臨床試驗市場預測：按治療領域、階段、應用、最終用戶和地區進行的全球分析

In Silico Clinical Trials Market Forecasts to 2030 - Global Analysis By Therapeutic Area, Phase, Application, End User and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球 In Silico 臨床試驗市場規模為 32.3 億美元，預計到 2030 年將達到 60.6 億美元，預測期內年複合成長率為 9.4%。

In Silico 臨床試驗，也稱為虛擬臨床試驗或計算臨床試驗，是製藥和醫療保健行業中使用的基於電腦的建模和模擬的一種型態。 In Silico 臨床試驗使用計算技術和數學模型來模擬臨床試驗、藥物開發和患者對藥物反應的各個方面。 In Silico 臨床試驗透過在進行人體或動物測試之前提供有價值的見解，減少了大規模且昂貴的物理測試的需要，加速了藥物開發並最佳化了治療策略，旨在提高患者的安全。

根據歐洲藥品管理局（歐盟）統計，EU/EEA每年核准超過4000項臨床試驗，其中60%由製藥公司贊助，40%由非商業贊助商贊助。

提高病人安全

In Silico 臨床試驗是一種藥物開發的變革性方法，透過電腦模擬取代或補充傳統的人體臨床試驗。這種方法大大降低了與人體實驗藥物測試相關的風險。 In Silico 研究透過使用虛擬患者模型來評估潛在的副作用、藥物交互作用和患者特異性反應，從而提高候選藥物的安全性。此外，此類測試使製藥公司能夠改進藥物配方並最佳化給藥，以最大限度地減少副作用並確保患者的更大安全。由於病患安全是製藥業的重中之重，In Silico 臨床試驗已成為提高整個藥物開發製程安全性的強大工具，使其成為市場成長和普及的關鍵驅動力。

跨學科問題

多學科挑戰是 In Silico 臨床試驗市場的主要抑制因素。 In Silico 臨床試驗需要來自不同領域的專家的合作，包括生物學、化學、藥理學、資料科學和電腦工程。有效地交流和整合這些領域的知識是複雜的，並且可能導致誤解、資料不相容和誤解。這些跨學科的挑戰減緩了研究和開發工作，阻礙了電腦模擬方法的採用，並且需要加強協調和標準化，以充分發揮這種創新方法在藥物開發方面的潛力。

人工智慧和機器學習技術的進步

人工智慧 (AI) 和機器學習 (ML) 技術的進步為 In Silico 臨床試驗市場創造了重大機會。這些技術透過預測患者反應、最佳化候選藥物和識別潛在副作用來提高電腦臨床試驗的精確度。此外，人工智慧和機器學習將促進新治療標靶的發現和現有藥物的重新利用，從而減少研究所需的時間和成本。隨著這些技術的不斷發展，電腦模擬臨床試驗市場將受益於效率的提高、藥物開發成功率的提高以及更有針對性和更有效的治療方法的潛力，最終將徹底改變製藥業。

缺乏標準化協議和法律規範

In Silico 測試依賴於計算模型和模擬，並且沒有普遍接受的標準，這可能會導致結果的變化和不一致。此外，法規機構可能難以建立明確的指導方針來評估和核准電腦研究，從而可能延遲其採用。缺乏標準化協議和法規引發了人們對 In Silico 測試結果可靠性和可信度的擔憂，阻礙了製藥和醫療保健行業的信任和接受。

COVID-19 的影響

COVID-19 大流行危機對多個行業造成了毀滅性影響。在此期間，使用電腦輔助藥物開發導致了電腦測試市場的顯著成長。隨著學術界、生物技術和生物製藥公司專注於預防冠狀病毒疾病傳播的研究和開發，使用計算模型進行電腦測試的需求正在增加。此外，隨著病毒的突變率不斷增加，科學家們正在努力尋找治療方法。因此，研究和藥物研發的重要性日益增加，刺激了醫療產品創新和法規批准的電腦模擬和模擬測試的增加。

預計腫瘤學領域將成為預測期內最大的領域

腫瘤學領域估計佔最大佔有率。 In Silico 臨床試驗透過利用電腦模擬和建模加速癌症治療方法的開發，為腫瘤學研究提供了突破性方法。這些模擬可以幫助評估候選藥物的有效性、預測患者反應並最佳化治療策略。鑑於癌症的複雜性和創新治療方法的緊迫性，腫瘤學中的電腦模擬臨床試驗可顯著節省成本和時間，並降低與傳統臨床試驗相關的風險。該領域在推進精準醫療和個體化癌症治療方面發揮關鍵作用，為改善癌症患者的治療結果帶來了希望。

製藥和生物技術公司細分市場預計在預測期內複合年複合成長率最高

預計製藥和生物技術公司部門在預測期內將出現良好成長。製藥和生物技術公司正在使用電腦模擬方法來簡化藥物研發發現和開發過程。電腦模擬測試採用電腦模擬和建模來預測藥物行為、最佳化配方並評估安全性和有效性。這種方法顯著降低了研發成本並加快了新藥的上市時間。它還能夠更有效地探索候選藥物，最大限度地減少昂貴且耗時的現場試驗的需要。此外，製藥和生物技術公司可以利用 In Silico 臨床試驗來加強其研究管道、推進技術創新，並最終為患者提供更安全、更有效的治療方法。

比最大的地區

在估計期間，亞太地區佔據最大的市場佔有率。推動這一成長的因素包括強勁的製藥和生物技術產業、龐大且多樣化的患者群體以及支持性的法規環境。 In Silico 臨床試驗利用電腦模擬和建模來評估藥物療效和安全性，為傳統臨床試驗提供了一種經濟高效的替代方案。這種方法不僅加快了藥物開發過程，而且還降低了與人體測試相關的成本和倫理問題。亞太地區對該技術的投資增加凸顯了其成為領先的 In Silico 臨床試驗中心的潛力，有助於加快藥物開發和改善醫療結果。

複合年複合成長率最高的地區：

預計北美在預測期內將實現盈利成長。北美是 In Silico 臨床試驗市場的重要中心。該地區擁有完善的製藥和生物技術部門，並不斷尋求創新解決方案來加速藥物開發。 In Silico 臨床試驗利用電腦模擬來評估藥物的安全性和有效性，由於其成本效益和速度而越來越受歡迎。大型製藥企業和尖端研究機構的存在進一步推動了這項技術的採用。此外，北美的法律規範和醫療保健基礎設施支持電腦臨床試驗的發展，使該地區成為透過計算建模和模擬來推進藥物藥物研發和開發的領導者。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球電腦模擬臨床試驗市場：依治療領域

  • 腫瘤學
  • 心臟病學
  • 糖尿病
  • 感染疾病
  • 神經病學
  • 血液學
  • 皮膚科
  • 其他治療領域

第6章 全球電腦模擬臨床試驗市場：依階段

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第7章 全球電腦模擬臨床試驗市場：依應用分類

  • 藥物開發
  • 治療最佳化
  • 醫療設備
  • 法規核准

第8章 全球電腦模擬臨床試驗市場：依最終使用者分類

  • 製藥和生物技術公司
  • 合約研究組織
  • 學術研究所
  • 其他最終用戶

第9章 全球電腦臨床試驗市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Certara, Inc.
  • Insilico Medicine, Inc.
  • Novadiscovery Sas
  • Dassault Systemes SE
  • The AnyLogic Company
  • GNS Healthcare Inc.
  • InSilicoTrials
  • Nuventra Pharma Sciences
  • Immunetrics Inc.
  • Abzena Ltd.
  • Clarivate
  • Evotec
  • Aitia
  • Allucent
  • Acellera Ltd.
Product Code: SMRC24210

According to Stratistics MRC, the Global In Silico Clinical Trials Market is accounted for $3.23 billion in 2023 and is expected to reach $6.06 billion by 2030 growing at a CAGR of 9.4% during the forecast period. In silico clinical trials, also known as virtual or computational clinical trials, are a form of computer-based modeling and simulation used in the pharmaceutical and healthcare industries. They involve the use of computational techniques and mathematical models to simulate various aspects of clinical trials, drug development, and patient responses to medications. In silico clinical trials aim to reduce the need for extensive and costly physical trials, accelerate drug development, optimize treatment strategies, and enhance patient safety by providing valuable insights before advancing to human or animal testing.

According to the European Medicines Agency - European Union, in the EU / EEA, more than 4,000 clinical trials are authorised each year, of which 60% of clinical trials are sponsored by the pharma industry and 40% by non-commercial sponsors.

Market Dynamics:

Driver:

Improved patient safety

In silico trials offer a transformative approach to drug development by replacing or supplementing traditional human trials with computer simulations. This method significantly reduces the risks associated with experimental drug testing on human subjects. In silico studies improve the safety profile of novel drug candidates by enabling the evaluation of possible side effects, drug interactions, and patient-specific responses through the use of virtual patient models. Furthermore, these trials enable pharmaceutical companies to refine drug formulations and optimise dosages to minimise side effects and ensure a higher level of safety for patients. As patient safety is a paramount concern in the pharmaceutical industry, in silico clinical trials provide a powerful avenue for enhancing the overall safety of drug development processes, making them a pivotal driver in the market's growth and adoption.

Restraint:

Interdisciplinary challenges

Interdisciplinary challenges serve as a significant restraint in the in silico clinical trial market. In silico trials require collaboration between experts from diverse fields, including biology, chemistry, pharmacology, data science, and computer engineering. Effective communication and integration of knowledge from these disciplines can be complex, potentially leading to misinterpretations, data incompatibility, or misunderstandings. These interdisciplinary challenges may slow down research and development efforts, hinder the adoption of in silico methods, and necessitate enhanced coordination and standardisation to unlock the full potential of this innovative approach in drug development.

Opportunity:

Advancements in artificial intelligence and machine learning technologies

Advancements in artificial intelligence (AI) and machine learning (ML) technologies present a significant opportunity in the in silico clinical trials market. These technologies enhance the precision of in silico clinical trials by predicting patient responses, optimising drug candidates, and identifying potential adverse effects. Furthermore, AI and machine learning empower the discovery of new therapeutic targets and the repurposing of existing drugs, reducing the time and cost required for research. As these technologies continue to evolve, the in silico clinical trials market stands to benefit from increased efficiency, improved success rates in drug development, and the potential for more tailored and effective treatments, ultimately revolutionising the pharmaceutical industry.

Threat:

Lack of standardized protocols and regulatory frameworks

In silico trials rely on computational models and simulations, and the absence of universally accepted standards can lead to variability and inconsistency in the results. Moreover, regulatory bodies may struggle to establish clear guidelines for evaluating and approving in silico trials, potentially delaying their adoption. The lack of standardised protocols and regulations raises concerns about the credibility and reliability of in silico trial outcomes, hindering trust and acceptance within the pharmaceutical and healthcare industries.

COVID-19 Impact

The COVID-19 pandemic crisis had a devastating effect on several industries. The use of computers to aid in drug development during this time led to a notable increase in the in-silico trial market. Because academics and biotechnological and biopharmaceutical businesses are working intensively on R&D for preventing the coronavirus disease from spreading, there is a greater need for in silico trials that use computational modelling. Furthermore, Scientists are working hard to find a cure for the COVID-19 pandemic as a result of the virus' rising mutation rate. As a result, the importance of research and drug discovery was increased, which in turn fueled the rise of the in silico computational modelling and simulation trials for medical product innovation and regulatory clearance.

The Oncology segment is expected to be the largest during the forecast period

The Oncology segment is estimated to hold the largest share. In silico clinical trials offer a groundbreaking approach to oncology research by utilising computer simulations and modelling to accelerate the development of cancer treatments. These simulations help assess drug candidates' efficacy, predict patient responses, and optimise treatment strategies. Given the complexity of cancer and the urgency for innovative therapies, in silico clinical trials in oncology offer significant advantages in terms of cost and time savings, as well as reduced risks associated with traditional clinical trials. This segment plays a pivotal role in advancing precision medicine and personalised cancer treatments, offering hope for improved outcomes for cancer patients.

The Pharmaceutical and Biotechnology Companies segment is expected to have the highest CAGR during the forecast period

The Pharmaceutical and Biotechnology Companies segment is anticipated to have lucrative growth during the forecast period. Pharmaceutical and biotechnology companies utilise in silico methods to streamline drug discovery and development processes. In silico trials employ computer simulations and modelling to predict drug behaviour, optimise formulations, and assess safety and efficacy. This approach significantly reduces research and development costs and expedites the time it takes to bring new drugs to market. It also enables a more efficient exploration of drug candidates, minimising the need for costly and time-consuming physical trials. Moreover, Pharmaceutical and biotechnology companies leverage in silico clinical trials to enhance their research pipelines, increase innovation, and ultimately deliver safer and more effective therapies to patients.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. Factors driving this growth include a robust pharmaceutical and biotechnology industry, a large and diverse patient population, and a supportive regulatory environment. In silico clinical trials, which utilise computer simulations and modelling to assess drug efficacy and safety, offer cost-effective and efficient alternatives to traditional clinical trials. This approach not only accelerates the drug development process but also reduces costs and the ethical concerns associated with human trials. The Asia-Pacific region's increasing investment in this technology highlights its potential to become a key hub for in silico clinical trials, contributing to faster drug development and improved healthcare outcomes.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America is a prominent hub in the in silico clinical trials market. The region boasts a well-established pharmaceutical and biotechnology sector, which continually seeks innovative solutions to expedite drug development. In silico clinical trials, which utilise computer-based simulations to assess drug safety and efficacy, are gaining traction due to their cost-efficiency and speed. The presence of major pharmaceutical companies and cutting-edge research institutions further drives the adoption of this technology. Additionally, North America's regulatory framework and healthcare infrastructure support the growth of in silico clinical trials, positioning the region as a leader in advancing drug discovery and development through computational modelling and simulations.

Key players in the market

Some of the key players in the In Silico Clinical Trials Market include: Certara, Inc., Insilico Medicine, Inc., Novadiscovery Sas, Dassault Systemes SE, The AnyLogic Company, GNS Healthcare Inc., InSilicoTrials, Nuventra Pharma Sciences, Immunetrics Inc., Abzena Ltd., Clarivate, Evotec, Aitia, Allucent and Acellera Ltd.

Key Developments:

In March 2022, QuantHealth partnered with 4P-Pharma to conduct AI-based in-Silico clinical trial simulations. In collaboration, the partnership would perform in silico clinical trials of their lead therapeutic candidates. The in-silico simulation of the phase II clinical trial of 4P004, a first-in-class disease-modifying osteoarthritis medication (DMOAD) developed by 4PPharma's spin-off, would kick off this comprehensive alliance.

In February 2022, IonsGate Preclinical Services and InSilicoTrials teamed up to revolutionize drug development. To digitalize IonsGate's drug development methods, InSilicoTrials would deliver a sophisticated modeling and simulation technology. This would reduce the cost and duration of preclinical testing while improving the safety of novel compounds.

Therapeutic Areas Covered:

  • Oncology
  • Cardiology
  • Diabetes
  • Infectious Disease
  • Neurology
  • Hematology
  • Dermatology
  • Other Therapeutic Areas

Phases Covered:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Applications Covered:

  • Drug Development
  • Treatment Optimization
  • Medical Devices
  • Regulatory Approval

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Academic and Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global In Silico Clinical Trials Market, By Therapeutic Area

  • 5.1 Introduction
  • 5.2 Oncology
  • 5.3 Cardiology
  • 5.4 Diabetes
  • 5.5 Infectious Disease
  • 5.6 Neurology
  • 5.7 Hematology
  • 5.8 Dermatology
  • 5.9 Other Therapeutic Areas

6 Global In Silico Clinical Trials Market, By Phase

  • 6.1 Introduction
  • 6.2 Phase I
  • 6.3 Phase II
  • 6.4 Phase III
  • 6.5 Phase IV

7 Global In Silico Clinical Trials Market, By Application

  • 7.1 Introduction
  • 7.2 Drug Development
  • 7.3 Treatment Optimization
  • 7.4 Medical Devices
  • 7.5 Regulatory Approval

8 Global In Silico Clinical Trials Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical and Biotechnology Companies
  • 8.3 Contract Research Organizations
  • 8.4 Academic and Research Institutes
  • 8.5 Other End Users

9 Global In Silico Clinical Trials Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Certara, Inc.
  • 11.2 Insilico Medicine, Inc.
  • 11.3 Novadiscovery Sas
  • 11.4 Dassault Systemes SE
  • 11.5 The AnyLogic Company
  • 11.6 GNS Healthcare Inc.
  • 11.7 InSilicoTrials
  • 11.8 Nuventra Pharma Sciences
  • 11.9 Immunetrics Inc.
  • 11.10 Abzena Ltd.
  • 11.11 Clarivate
  • 11.12 Evotec
  • 11.13 Aitia
  • 11.14 Allucent
  • 11.15 Acellera Ltd.

List of Tables

  • Table 1 Global In Silico Clinical Trials Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 3 Global In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 4 Global In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 5 Global In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 6 Global In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 7 Global In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 8 Global In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 9 Global In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 10 Global In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 11 Global In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 12 Global In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 13 Global In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 14 Global In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 15 Global In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 16 Global In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 18 Global In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 19 Global In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 20 Global In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 21 Global In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 22 Global In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 23 Global In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 24 Global In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 25 Global In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 26 North America In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
  • Table 27 North America In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 28 North America In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 29 North America In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 30 North America In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 31 North America In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 32 North America In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 33 North America In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 34 North America In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 35 North America In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 36 North America In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 37 North America In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 38 North America In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 39 North America In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 40 North America In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 41 North America In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 42 North America In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 43 North America In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 44 North America In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 45 North America In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 46 North America In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 47 North America In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 48 North America In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 49 North America In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 50 North America In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 51 Europe In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
  • Table 52 Europe In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 53 Europe In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 54 Europe In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 55 Europe In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 56 Europe In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 57 Europe In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 58 Europe In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 59 Europe In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 60 Europe In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 61 Europe In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 62 Europe In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 63 Europe In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 64 Europe In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 65 Europe In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 66 Europe In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 67 Europe In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 68 Europe In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 69 Europe In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 70 Europe In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 71 Europe In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 72 Europe In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 73 Europe In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 74 Europe In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 75 Europe In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 76 Asia Pacific In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Asia Pacific In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 78 Asia Pacific In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 79 Asia Pacific In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 80 Asia Pacific In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 81 Asia Pacific In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 82 Asia Pacific In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 83 Asia Pacific In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 84 Asia Pacific In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 85 Asia Pacific In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 86 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 87 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 88 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 89 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 90 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 91 Asia Pacific In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 92 Asia Pacific In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 93 Asia Pacific In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 94 Asia Pacific In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 95 Asia Pacific In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 96 Asia Pacific In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 97 Asia Pacific In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 98 Asia Pacific In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 99 Asia Pacific In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 100 Asia Pacific In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 South America In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 South America In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 103 South America In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 104 South America In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 105 South America In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 106 South America In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 107 South America In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 108 South America In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 109 South America In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 110 South America In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 111 South America In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 112 South America In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 113 South America In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 114 South America In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 115 South America In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 116 South America In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 117 South America In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 118 South America In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 119 South America In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 120 South America In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 121 South America In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 122 South America In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 123 South America In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 124 South America In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 125 South America In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 126 Middle East & Africa In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
  • Table 127 Middle East & Africa In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 128 Middle East & Africa In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 129 Middle East & Africa In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 130 Middle East & Africa In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 131 Middle East & Africa In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
  • Table 132 Middle East & Africa In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 133 Middle East & Africa In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 134 Middle East & Africa In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 135 Middle East & Africa In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 136 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
  • Table 137 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
  • Table 138 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
  • Table 139 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
  • Table 140 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
  • Table 141 Middle East & Africa In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
  • Table 142 Middle East & Africa In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
  • Table 143 Middle East & Africa In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
  • Table 144 Middle East & Africa In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 145 Middle East & Africa In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
  • Table 146 Middle East & Africa In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
  • Table 147 Middle East & Africa In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 148 Middle East & Africa In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 149 Middle East & Africa In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 150 Middle East & Africa In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)